PM
NKTR icon

Prosight Management’s Nektar Therapeutics NKTR Stock Holding History

Prosight Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.5M Buy
810,000
+75,000
+10% +$5.49M 9.74% 3
2026
Q1 		$52.9M Buy
735,000
+180,367
+33% +$10.3M 8.67% 1
2025
Q4 		$23.4M Buy
+554,633
New +$31M 4.85% 7

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosight Management's NKTR Position: Q2 2026 in Review

Prosight Management increased its Nektar Therapeutics (NKTR) stake by 10% in Q2 2026, buying an estimated $5.49M and bringing the position to 810,000 shares worth $56.5M. The position accounts for 9.74% of the portfolio, ranked #3.

Prosight Management first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Prosight Management held 810,000 shares of Nektar Therapeutics worth $56.5M as of Q2 2026.
  • Prosight Management bought 75,000 Nektar Therapeutics shares in Q2 2026, an estimated $5.49M.
  • Nektar Therapeutics made up 9.74% of Prosight Management's portfolio in Q2 2026, its #3 holding.
  • Prosight Management first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.